| (Values in U.S. Thousands) | Jun, 2023 | Mar, 2023 | Dec, 2022 | Sep, 2022 | Jun, 2022 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -2,110 | -4,090 | -4,080 | -2,800 | -4,190 |
| Net Income Growth | +48.41% | -0.25% | -45.71% | +33.17% | +7.51% |
Diffusion Pharmaceuticals Inc (DFFN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Diffusion Pharmaceuticals Inc. is a biotechnology company. Its product pipeline includes Trans Sodium Crocetinate, Glioblastoma Program, Pancreatic Cancer Program and Brain Metastases Program. The Company is focused on cancer treatments, such as radiation therapy and chemotherapy in treatment-resistant solid tumors. Diffusion Pharmaceuticals Inc., formerly known as RestorGenex Corporation, is based in Charlottesville, United States.